Emergent Biosolutions Inc. · NYSE:EBS
Emergent Biosolutions — 40th Annual J.P. Morgan Healthcare Conference (January 2022)
22 slides from Emergent Biosolutions's conference presentation, Jan 10, 2022
Slide 1: Our Path Forward
Our Path Forward Robert G. Kramer President & Chief Executive Officer 40th Annual J.P. Morgan Healthcare Conference January 10, 2022
Slide 2: Forward-looking statements
This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, our financial guidance and related projections and statements regarding our abili
Slide 3: Non-GAAP Financial Measures
This presentation contains two financial measures Adjusted EBITDA (Earnings Before Interest, Taxes, and Depreciation and Amortization) and Adjusted EBITDA Margin, both of which are considered “non-GAAP” financial measures under applicable Securities and Exchange Commission rules and regulations. The
Slide 4: What We're Going to Cover Today
What We’re Going to Cover Today 440th Annual J.P. Morgan Healthcare Conference The Company • Our Vision • Introduction Business Performance • Government/Medical Countermeasures (MCM) Products Business • Commercial Products Business • Research & Development (R&D) • Contract Development & Manufacturin
Slide 5: Who We Are: Our Vision | Introduction
PROPRIETARY AND CONFIDENTIAL 540th Annual J.P. Morgan Healthcare Conference Who We Are Our Vision | Introduction
Slide 6: Who We Are
W H O W E A R E We develop, manufacture, and deliver protections against public health threats through a pipeline of innovative vaccines and therapeutics. For over 20 years, we’ve been at work defending people from things we hope will never happen — so that we’re prepared, just in case they ever do.
Slide 7: Emergent At-A-Glance
Emergent At-A-Glance 740th Annual J.P. Morgan Healthcare Conference THE COMPANY | INTRODUCTION PUBLIC HEALTH THREAT PREPAREDNESS AND RESPONSE SOLUTIONS PRODUCTS BUSINESS G O V E R N M E N T / M C M C O M M E R C I A L C O N T R A C T D E V E L O P M E N T & M A N U F A C T U R I N G ( C D M O ) SERV
Slide 8: Business Performance
PROPRIETARY AND CONFIDENTIAL40th Annual J.P. Morgan Healthcare Conference Business Performance Government/MCM Products Business | Commercial Products Business | Research & Development | CDMO Services Business 8
Slide 9: Government/Medical Countermeasures MCM Products
940th Annual J.P. Morgan Healthcare Conference BUSINESS PERFORMANCE | GOVERNMENT/MEDICAL COUNTERMEASURES L O N G - T E R M G R O W T H O P P O R T U N I T I E S • Continue to support product requirements of the US Strategic National Stockpile (SNS) • Continue to support active use needs of multiple
Slide 10: Opioid Use Disorder and Travel Health Franchises
Opioid Use Disorder and Travel Health Franchises Provide Opportunity to Impact Patients and Customers 1040th Annual J.P. Morgan Healthcare Conference BUSINESS PERFORMANCE | COMMERCIAL L O N G - T E R M G R O W T H O P P O R T U N I T I E S • Continue to sell branded NARCAN Nasal Spray • Initiate mod
Slide 11: Diverse R&D Portfolio Offers Potential for Expanded Impact
Diverse R&D Portfolio Offers Potential for Expanded Impact to Global Public Health 1140th Annual J.P. Morgan Healthcare Conference BUSINESS PERFORMANCE | RESEARCH & DEVELOPMENT P R O G R A M E X T E R N A L P A R T N E R C U R R E N T S T A T U S AV7909 (Anthrax Vaccine Adsorbed (AVA), Adjuvanted) B
Slide 12: Biologics CDMO Services Remain Well-Positioned
Biologics CDMO Services Remain Well-Positioned to Support Needs of Global Pharma/Biotech Innovators 1240th Annual J.P. Morgan Healthcare Conference BUSINESS PERFORMANCE | CDMO SERVICES BUSINESS L O N G - T E R M G R O W T H O P P O R T U N I T I E S • Increase network utilization • Drive a higher mi
Slide 13: 120M+ Dose Equivalents of COVID-19 Vaccine Released
120M+ Dose Equivalents of COVID-19 Vaccine Released for Global Distribution Bayview Facility Represents Significant Contributor to Potential Future Growth and Impact 1340th Annual J.P. Morgan Healthcare Conference BUSINESS PERFORMANCE | BAYVIEW SITE UPDATE 2 0 2 1 A C C O M P L I S H M E N T S • Com
Slide 14: Financials: 2021 Preliminary | 2022 Guidance
PROPRIETARY AND CONFIDENTIAL 1440th Annual J.P. Morgan Healthcare Conference Financials 2021 Preliminary | 2022 Guidance
Slide 15: Financial Performance Reflects Track Record of Diversified Profitable Revenue Growth
2017 2018 2019 2020 2021E 2022G 2024G T O T A L R E V E N U E S 1 , 2 ( $ M ) 1540th Annual J.P. Morgan Healthcare Conference FINANCIALS | 2021 PRELIMINARY & 2022 GUIDANCE 1. 2021E (preliminary and unaudited) and 2022G (guidance) reflect the ranges provided in the press release issued by the Company
Slide 16: Key Takeaways
PROPRIETARY AND CONFIDENTIAL 1640th Annual J.P. Morgan Healthcare Conference Key Takeaways
Slide 17: Business on track to achieve 2024 goals
Business on track to achieve 2024 goals Summary 1740th Annual J.P. Morgan Healthcare Conference KEY TAKEAWAYS New operating structure focused on customers and markets Strong manufacturing network with capacity for growth Continued focus on M&A to drive diversified profitable revenue growth Broad R&D
Slide 18: Appendix
1840th Annual J.P. Morgan Healthcare Conference Appendix
Slide 19: Reconciliation of Net Income to Adjusted EBITDA
Reconciliation of Net Income to Adjusted EBITDA 2022G and 2021E-2017 (unaudited) 1940th Annual J.P. Morgan Healthcare Conference APPENDIX * Includes interest income of $0.5M in 2022G, $0.6M in 2021E and $1.1M in 2020. Full Year Guidance 2022G 2021E 2020 2019 2018 2017 Net Income $85.0 - $130.0 $260.
Slide 20: The Chikungunya Virus (CHIKV)
Virology • Alphavirus, vector-borne, three genotypes • Enveloped RNA virus • Acute febrile illness with symptoms including fever, fatigue, and incapacitating joint pain • Many patients develop chronic arthritis and arthralgia which may persist for years The Chikungunya Virus (CHIKV) 2040th Annual J.
Slide 21: Emergent's CHIKV VLP Vaccine Designed to Mimic Natural Immune Response
VLP vaccine candidate comprised of three chikungunya structural proteins (Capsid, Envelope proteins 1 and 2) • Structure is indistinguishable from authentic virus by EM • Non-replicating, subunit vaccine Target indication is for active immunization to prevent CHIKV disease Presentation: • Aluminum h
Slide 22: www.emergentbiosolutions.com
www.emergentbiosolutions.com
Emergent BioSolutions — 40th Annual J.P. Morgan Healthcare Conference (January 2022) on 6ix